Literature DB >> 16352258

Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease.

David R Sullivan1, Malcolm West, Richmond Jeremy.   

Abstract

Cardiac failure is a prevalent and costly condition in Western society. The ageing of the population, together with current medical options which improve, rather than eradicate heart failure, lead to the projection that this problem will increase substantially in the foreseeable future. The availability of a simple test to assist the diagnosis and effective management of heart failure would greatly assist the clinical approach to this problem. This review examines the physiological basis for the measurement of natriuretic peptides as markers of the presence or risk of heart failure. It considers its use in the hospital and non-hospital setting and examines the cost-effectiveness of current assays. It is possible that in future natriuretic peptides may offer a form of treatment for heart failure, but this is beyond the scope of this review. Nevertheless, the review highlights the potential benefits of this group of tests in the management of heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352258     DOI: 10.1016/j.hlc.2005.03.002

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  4 in total

1.  The effects of acute oral antioxidants on diving-induced alterations in human cardiovascular function.

Authors:  Ante Obad; Ivan Palada; Zoran Valic; Vladimir Ivancev; Darija Baković; Ulrik Wisløff; Alf O Brubakk; Zeljko Dujić
Journal:  J Physiol       Date:  2006-11-16       Impact factor: 5.182

2.  Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients.

Authors:  Reneta Yovcheva Koycheva; Vasil Cholakov; Jivko Andreev; Margarit Penev; Rosen Iliev; Krasimira Nancheva; Vanya Tsoneva
Journal:  Open Access Maced J Med Sci       Date:  2015-12-30

3.  ANP and BNP plasma levels in patients with rheumatic mitral stenosis after percutaneous balloon mitral valvuloplasty.

Authors:  Łukasz Mazurkiewicz; Witold Rużyłło; Zbigniew Chmielak; Ewa Opalińska-Ciszek; Jadwiga Janas; Piotr Hoffman; Tomasz Hryniewiecki; Jacek Grzybowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-03-10       Impact factor: 1.426

4.  Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease.

Authors:  Hyo Min Park; Dong Won Lee; Myung Chul Hyun; Sang Bum Lee
Journal:  Korean J Pediatr       Date:  2013-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.